A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

Sponsor
StemCyte, Inc.
Study ID
NCT07184385
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • REGENECYTE — BIOLOGICAL
    HPC, Cord Blood
  • Placebo — BIOLOGICAL
    Normal Saline

Study Details

REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.

Key Dates

First listed
Sep 19, 2025
Start date
Mar 31, 2026
Status verified
Sep 2025
Primary completion
Jun 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: REGENECYTE
    HPC, Cord Blood
  • Placebo Comparator: Placebo
    Normal Saline

Primary Outcome Measure

The change of efficacy [ Time Frame: Week ]

Central Contacts

Find similar trials

Nationwide
COVID-19 / long COVID trialsInfectious disease trials

Related Studies